Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: October Update

Performance overview

Value at beginning of month: $160,225.58

Value at end of month: $131,204.33

Month over month change: -18.11%

Total IRR: 16.40%

Related indices, monthly change

NASDAQ: -10.93%

IVV (iShares Core S&P 500): -8.76%

IBB (iShares NASDAQ Biotechnology Index): -15.03%

MXI (iShares Global Materials): -11.53%

VEGI (iShares MSCI Global Agriculture Producers): -8.77%

ICLN (iShares Clean Energy): -6.05%

Individual performances

g4165.png

Ouch. This month really hurt the index, as it fell from almost yearly highs to a negative year-to-date return. Though the index had a rough month, it was a market as a whole that cratered, with biotech stocks suffering a bit more than others. Almost every single position lost value (way to go Dyadic!), with some losing almost a third of their value. Hopefully November is better!

Changes made to index

None.

You can view the index here.

Allocation as of October 26, 2018

g4730.png

Calvin Schmidt Synthetic Biology Index: November Update

Synthetic biology investors are a mix of life sciences and traditional technology investors